(Q30794078)

26 June 2017

title

The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model (English)

1 reference

26 June 2017

0 references

1 reference

1 reference

Jinbo Fang

1

1 reference

26 June 2017

Guiyun Wang

2

1 reference

26 June 2017

Qiong Yang

3

1 reference

26 June 2017

Jinna Song

4

1 reference

26 June 2017

Ye Wang

5

1 reference

26 June 2017

Li Wang

6

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

26 June 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

26 June 2017

volume

23

1 reference

26 June 2017

issue

40

1 reference

26 June 2017

page(s)

4860-4866

1 reference

Expression of MAGE-antigens in normal tissues and cancer

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Immunomic analysis of human sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Recognition of HIV-derived B and T cell epitopes displayed on filamentous phages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV-1 gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Human natural killer cell function and receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

T cell-mediated immune responses in melanoma: implications for immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Expression of the MAGE gene family in human hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

The role of CD4+ T cell responses in antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Molecular models and structural comparisons of native and mutant class I filamentous bacteriophages Ff (fd, f1, M13), If1 and IKe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

MHC class I-restricted CTL responses to exogenous antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.024

10.1016/J.VACCINE.2005.05.024

7 January 2021

Identifiers

DOI

1 reference

26 June 2017

1 reference